Vopratelimab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Vopratelimab (JTX-2011) 是一种人源化免疫球蛋白 G1-kappa 激动剂单克隆抗体，特异性结合到诱导型 T 细胞 CO 刺激因子 (ICOS)。Vopratelimab 保留了物种交叉反应性，对 hICOS 的亲和力为 0.93 nM，对大鼠 ICOS 的亲和力为 3.7 nM，对 mICOS 的亲和力为 0.64 nM。Vopratelimab 具有抗肿瘤免疫反应。

Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response.

——

Animal Model:Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model Dosage:0.25-0.3 mg/kg Administration:Intraperitoneal injection; twice a week, for 2 weeks Result:Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.

——

Others

Other Targets

Others

——

——

2039148-04-2

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years